SÜSLEYİCİ, B. Et Al. 2021. Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017. Current Pharmacogenomics and Personalized Medicine , vol.18, no.2 , 116-122.

SÜSLEYİCİ, B., Ciftci, C., Yurdakul, S., Cevik, M., Akdeniz, C. S., Canbolat, I. P., ... Deliorman, G.(2021). Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017. Current Pharmacogenomics and Personalized Medicine , vol.18, no.2, 116-122.

SÜSLEYİCİ, BELGİN Et Al. "Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017," Current Pharmacogenomics and Personalized Medicine , vol.18, no.2, 116-122, 2021

SÜSLEYİCİ, BELGİN Et Al. "Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017." Current Pharmacogenomics and Personalized Medicine , vol.18, no.2, pp.116-122, 2021

SÜSLEYİCİ, B. Et Al. (2021) . "Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017." Current Pharmacogenomics and Personalized Medicine , vol.18, no.2, pp.116-122.

@article{article, author={BELGİN SÜSLEYİCİ Et Al. }, title={Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017}, journal={Current Pharmacogenomics and Personalized Medicine}, year=2021, pages={116-122} }